Souhaitez-vous accéder aux communiqués récents ?

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call...

In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was...

PETAH TIKVA, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services,...

Nephros Schedules Fourth Quarter 2025 Financial Results Conference Call

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of...

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO,...

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s...

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCash,...

Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder...

ATHENS, Greece, March 05, 2026 (GLOBE NEWSWIRE) -- Capital Clean Energy Carriers Corp. (the “Company”, “CCEC”, “we” or “us”) (NASDAQ: CCEC), an international owner of ocean-going vessels, today...